RESIDUAL HEMATOPOIETIC STEM CELLS REFLECT MINIMAL RESIDUAL DISEASE AND PREDICT OUTCOME IN ACUTE MYELOID LEUKEMIA

EHA Library, Wenwen Wang, 100442

ALLOGENEIC TRANSPLANT IN PATIENTS ≥60 YEARS OF AGE WITH FIRST RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA AFTER TREATMENT WITH VOSAROXIN OR PLACEBO PLUS CYTARABINE: RESULTS FROM VALOR

EHA Library, Farhad Ravandi, 100443

RELAPSE CHARACTERISTICS AND RISK FACTORS FOR CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ACUTE PROMYELOCYTIC LEUKAEMIA IN THE ORAL ARSENIC TRIOXIDE ERA – A 13-YEAR FOLLOW-UP STUDY

EHA Library, Harinder Gill, 100444

PROSPECTIVE STUDY ON 220 NEUTROPENIC EPISODES IN 109 AML PATIENTS. ROLE OF BED-SIDE ULTRASOUND (BUS) IN NEUTROPENIC ENTEROCLITIS (NEC): INCIDENCE AND SURVIVAL WITH DIFFERENT CHEMOTHERAPY REGIMEN.

EHA Library, Edoardo Benedetti, 100445

MGA GUIDED INTENSIVE INDUCTION WITH HIGH DOSE CYTARABINE PLUS IDARUBICIN IN 149 AML ELDERLY PATIENTS

EHA Library, Debora Capelli, 100446

CD200 EXPRESSION IS ASSOCIATED WITH INFERIOR RESPONSE AND POOR SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Mario Tiribelli, 100447

SALVAGE REGIMENT WITH FRACTIONATED GEMTUZUMAB OZOGAMICIN, INTERMEDIATE DOSE CYTARABINE AND MITOXANTRONE (MYLODAM) FOR REFRACTORY AND RELAPSED AML: A SINGLE CENTER EXPERIENCE.

EHA Library, Anne-Claire Mamez, 100448

EARLY PERIPHERAL BLAST CELL CLEARANCE PREDICTS MINIMAL RESIDUAL DISEASE STATUS AFTER INDUCTION IN ACUTE MYELOID LEUKEMIA

EHA Library, Francesco Mannelli, 100449

MICRODUPLICATION 17Q21.31 AND 17P11.2 ASSOCIATE WITH AML DIAGNOSIS OR RESPONSE TO THE THERAPY

EHA Library, Andrzej Lange, 100450

THE SIGNIFICANCE OF RELATIVE MUTANT LEVEL FOR C-KIT MUTATION IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA BY ALLELE-SPECIFIC REAL-TIME PCR

EHA Library, Eunhee Han, 100451

IMPROVED SURVIVAL IN PATIENTS ≥60 WITH FIRST RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA TREATED WITH VOSAROXIN PLUS CYTARABINE VS PLACEBO PLUS CYTARABINE: RESULTS FROM THE PHASE 3 VALOR STUDY

EHA Library, Farhad Ravandi, 100452

IMPORTANCE OF THE B-CELL RECEPTOR ISOTYPE FOR SIGNALING AND FUNCTIONAL RESPONSES IN B CELLS FROM PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Jan Burger, 100453

HIGHER-ORDER IMMUNOGLOBULIN SEQUENCE RELATIONS FOR MAJOR SUBSETS OF CHRONIC LYMPHOCYTIC LEUKEMIA: UNIQUENESS VERSUS EQUIVALENCE

EHA Library, Andreas Agathangelidis, 100454

STEM CELL FACTOR KLF4 IS EPIGENETICALLY INACTIVATED AND REPRESSED BY NOTCH SIGNALING IN CLL

EHA Library, Daniel Mertens, 100455

NOTCH2 AND NOTCH3 HAVE OPPOSITE ROLES IN THE REGULATION OF APOPTOSIS IN CLL CELLS

EHA Library, Rainer Hubmann, 100456

EXPRESSION AND FUNCTIONAL ROLE OF CORTACTIN IN AGRESSIVENESS AND DIFFUSION OF CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Veronica Martini, 100457

ROLE OF HAUSP/PTEN NETWORK IN CHRONIC LYMPHOID LEUKEMIA PATHOGENESIS AND THERAPY

EHA Library, Alessandro Morotti, 100458

UPREGULATED COBLL1 IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) PATIENTS WITH UNMUTATED IGHV IDENTIFIES A COHORT WITH INFERIOR PROGNOSIS

EHA Library, Hana Plešingerová, 100459

EXTRACELLULAR VESICLES FROM MESENCHYMAL STROMAL CELL MICROENVIRONMENT PROTECT CHRONIC LYMPHOCYTIC LEUKEMIA B-CELLS FROM APOPTOSIS

EHA Library, Emerence Crompot, 100460

FUNCTIONAL INVOLVEMENT OF THE SRC KINASE LYN IN THE SURVIVAL OF CHRONIC LYMPHOCYTIC LEUKEMIA CELLS VIA MAINTENANCE OF ANTI-APOPTOTIC B CELL RECEPTOR SIGNALING

EHA Library, Verena Vondey, 100461

THE COMBINATION OF ARSENIC TRIOXIDE AND IBRUTINIB INDUCES SYNERGISTIC APOPTOSIS IN CHRONIC LYMPHOCYTIC LEUKAEMIA THAT IS POTENTLY ASSOCIATED WITH PI3K-AKT DOWN-REGULATION

EHA Library, Yan Su, 100462

REFINING PROGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH SOMATICALLY HYPERMUTATED B-CELL RECEPTORS: A NOVEL PROGNOSTIC INDEX ON BEHALF OF THE EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC)

EHA Library, Panagiotis Baliakas, 100463

LONG-TERM FOLLOW-UP OF A PHASE IB TRIAL OF IDELALISIB IN COMBINATION WITH CHEMOIMMUNOTHERAPY (CIT) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CLL INCLUDING PATIENTS WITH DEL17P/TP53 MUTATION

EHA Library, Jacqueline Barrientos, 100464

A RANDOMISED DE-ESCALATION STUDY OF ORAL FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB IN FIT ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA: WELL TOLERATED AND SUPERIOR OUTCOMES WITH FCR

EHA Library, Stephen Mulligan, 100465

CLINICAL ASSESSMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA SAMPLES FOR SOMATIC HYPERMUTATION STATUS BY NEXT-GENERATION SEQUENCING AND SANGER SEQUENCING

EHA Library, Ying Huang, 100466

HEALTH RELATED QUALITY OF LIFE AND PATIENT REPORTED OUTCOMES IN PATIENTS RECEIVING OFATUMUMAB MAINTENANCE VERSUS OBSERVATION IN THE PROLONG TRIAL

EHA Library, Stephanie Manson, 100467

QUALITY OF LIFE BENEFITS OF IDELALISIB WITH RITUXIMAB FOR PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKAEMIA

EHA Library, Rodolphe Perard, 100468

CHRONIC LYMPHOCYTIC LEUKEMIA MD ANDERSON CANCER CENTER PROGNOSTIC INDEX IS SUCCESSFUL BUT STILL CAN BE IMPROVED BY INCORPORATING SERUM LDH LEVEL

EHA Library, Nilgun Sayinal, 100469

GENETIC BASIS OF HAIRY CELL LEUKEMIA (BRAF) REVEALS HIGH FREQUENCIES OF MUTATIONS IN BRAF V600E, U2AF1 AND MAP2K1 GENES

EHA Library, Sheetal Gaware, 100470

LLC-LENAR-08 A PHASE I/II STUDY LENALIDOMIDE-RITUXIMAB IN RELAPSE/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Adolfo De La Fuente, 100471

TRANSCRIPTION FACTOR MEF2C IS UPREGULATED DURING CML DISEASE PROGRESSION AND INHIBITS C/EBPΑ EXPRESSION

EHA Library, Soumen Chakraborty, 100472

MESENCHYMAL STEM CELLS FROM CML PATIENTS REGULATE MYELOID DERIVED SUPPRESSOR CELLS ACTIVATION

EHA Library, Cesarina Giallongo, 100473

DO ENDOTHELIAL CELLS BELONG TO THE PRIMITIVE LEUKEMIC CLONE IN CML? ¬ ROLE OF EXTRACELLULAR VESICLES

EHA Library, Fermin Sanchez-Guijo, 100474

IDENTIFICATION OF BRD4 AS A NOVEL MOLECULAR TARGET IN PH+ CML

EHA Library, Barbara Peter, 100475

QUANTITATIVE EVALUATION OF BOTH POINT MUTATED AND ALTERNATIVELY SPLICED BCR-ABL IN CML-CP PATIENT WITH SUBOPTIMAL MOLECULAR RESPONSE TO IMATINIB: RESULT OF HIGHLY-SENSITIVE, DEEP SEQUENCING STUDY

EHA Library, Junichiro Yuda, 100476

AN ITALIAN MULTICENTRIC EVALUATION OF THE Q-LAMP TECHNOLOGY APPLIED TO THE MOLECULAR DETECTION OF BCR-ABL TRANSCRIPTS IN ARCHIVED RNA FROM PHILADELPHIA POSITIVE ONSET SAMPLES

EHA Library, Maria Teresa Bochicchio, 100477

DYNAMIC EXPANSION AND FUNCTIONAL TUNING OF NATURAL KILLER CELLS IN CHRONIC MYELOID LEUKEMIA

EHA Library, Paulo Rodrigues-Santos, 100478

IS THE HIGH-THROUGHPUT DROPLET DIGITAL PCR A NEXT-GENERATION TECHNOLOGY FOR ACCURATE AND SENSITIVE BCR-ABL1 QUANTIFICATION FOR DEEP MOLECULAR RESPONSE MONITORING IN CML?

EHA Library, Hana Zizkova, 100479

EFFICACY AND SAFETY OF NILOTINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: 6-YEAR FOLLOW-UP OF ENESTND

EHA Library, Tim Hughes, 100480

ENESTCMR 4-Y RESULTS: PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND RESIDUAL DISEASE MORE LIKELY TO ACHIEVE DEEP MOLECULAR RESPONSE FOLLOWING SWITCH TO NILOTINIB (NIL)

EHA Library, Tim Hughes, 100481

DEEP MOLECULAR RESPONSE TO NILOTINIB AS FIRST-LINE TREATMENT OF BCR-ABL+ CML

EHA Library, Fausto Castagnetti, 100482

SMOOTHENED (SMO) INHIBITOR LDE225 COMBINED WITH NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) RESISTANT/INTOLERANT (R/I) TO AT LEAST 1 PRIOR TYROSINE KINASE INHIBITOR: A PHASE 1B STUDY

EHA Library, Oliver Ottmann, 100483

FINAL LASOR RESULTS: SWITCH TO NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND SUBOPTIMAL CYTOGENETIC RESPONSE (CYR) TO FRONTLINE IMATINIB (IM)

EHA Library, Philipp Le Coutre, 100484

HEALTH-RELATED QUALITY OF LIFE IN CML PATIENTS UNDER NILOTINIB FIRST-LINE TREATMENT: RESULTS OF A GERMAN SUB-STUDY WITHIN THE ENEST1ST TRIAL

EHA Library, Insa Lütge, 100485

PONATINIB EFFICACY AND SAFETY IN HEAVILY PRETREATED LEUKEMIA PATIENTS: 3-YEAR RESULTS OF THE PACE TRIAL

EHA Library, Jorge Cortes, 100486

RESPONSES AT EARLY LANDMARK TIME POINTS ARE ASSOCIATED WITH OUTCOMES IN HEAVILY PRETREATED CP-CML PATIENTS (PTS) TREATED WITH PONATINIB

EHA Library, Martin Müller, 100487

LONG-TERM FOLLOW-UP OF PONATINIB EFFICACY AND SAFETY IN PATIENTS (PTS) WITH THE T315I MUTATION IN THE PHASE 1 AND PHASE 2 (PACE) TRIALS

EHA Library, Michele Baccarani, 100488

MINIMUM FOLLOW-UP OF 4 YEARS FOR ONGOING PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN A PHASE 1 TRIAL OF PONATINIB

EHA Library, Moshe Talpaz, 100489

HYPOPLASTIC MYELODYSPLASTIC SYNDROME (H-MDS): DISTINCT CLINICO-BIOLOGICAL FEATURES AND PROGNOSTIC RELEVANCE

EHA Library, Chi-Yuan Yao, 100490

LONG-TERM OUTCOME OF LOWER RISK MDS PATIENTS RECEIVING ESA, AND IMPACT OF POST ESA TREATMENTS ON SURVIVAL: A RETROSPECTIVE STUDY FROM THE GFM, DUSSELDÖRF, AND GESMD REGISTRIES

EHA Library, Sophie Park, 100491

EVALUATION OF DYSPLASIAS IN 1979 PATIENTS WITH MYELODYSPLASTIC SYNDROMES COLLECTED IN A GERMAN-AUSTRIAN DATA SET TO APPROACH THE HETEROGENEITY OF THE DISEASE

EHA Library, Michael Pfeilstöcker, 100492

RANDOMIZED, PLACEBO (PBO)-CONTROLLED, PHASE I/II TRIAL OF THE THROMBOPOIETIN RECEPTOR AGONIST ELTROMBOPAG (EPAG) IN THROMBOCYTOPENIC PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES (MDS)

EHA Library, Uwe Platzbecker, 100493

THE EFFECT OF LENALIDOMIDE ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: RESULTS FROM THE MDS-005 TRIAL

EHA Library, Valeria SANTINI, 100494

IMPACT OF MDS ON HEALTH-RELATED QUALITY OF LIFE: A COMPARISON OF IPSS LOW- AND INT-1 RISK MDS PATIENTS FROM THE EUROPEAN LEUKEMIANET MDS (EUMDS) REGISTRY AND EUROPEAN REFERENCE POPULATIONS

EHA Library, Reinhard Stauder, 100495

SPRESAS (SPANISH REGISTRY OF ERYTHROPOIETIC STIMULATING AGENTS STUDY): THE LARGEST RETROSPECTIVE STUDY OF TREATMENT WITH ESAS IN LOWER RISK MDS

EHA Library, María Díez Campelo, 100496

MDS-005 STUDY: EFFECT OF BASELINE ENDOGENOUS ERYTHROPOIETIN ON RBC TRANSFUSION INDEPENDENCE IN LENALIDOMIDE-TREATED PATIENTS WITH LOW OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES WITHOUT DEL(5Q)

EHA Library, Valeria SANTINI, 100497

PROGNOSTIC IMPACT OF CHROMOSOMAL TRANSLOCATIONS IN MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA PATIENTS. A STUDY BY THE SPANISH GROUP OF MYELODYSPLASTIC SYNDROMES.

EHA Library, Meritxell Nomdedeu, 100498

SUPERIOR LONG-TERM OUTCOMES OF LOWER RISK MDS PATIENTS WHEN TRANSPLANTED IN RESPONSE COMPARED TO RELAPSED OR REFRACTORY TO HMA

EHA Library, Yoo JinLee, 100499

THE MTOR SIGNALING PATHWAY IS ACTIVIVED IN T CELLS OF APLASTIC ANEMIA

EHA Library, Guangsheng He, 100500

THE PREVALENCE OF GATA-2 MUTATION AMONG PEDIATRIC PATIENTS WITH MYELODYSPLASTIC SYNDROME IN CZECH REPUBLIC

EHA Library, Michaela Reiterová, 100501

EVALUATION OF BONE MARROW MICROVESSEL DENSITY IN PATIENTS WITH APLASTIC ANEMIA AND ITS ROLE IN PREDICTING OUTCOME TO THERAPY.

EHA Library, Somasundaram Venkatesan, 100502

IMMUNOPHENOTYPIC PROFILING OF ERYTHROID PROGENITOR-DERIVED EXTRACELLULAR VESICLES IN DIAMOND-BLACKFAN ANAEMIA: A NEW DIAGNOSTIC STRATEGY

EHA Library, Serena Macrì, 100503

ALTERATION OF HEME METABOLISM IN A CELLULAR MODEL OF DIAMOND-BLACKFAN ANEMIA

EHA Library, Deborah Chiabrando, 100504

AUTOIMMUNE NEUTROPENIA OF INFANCY: DATA FROM THE ITALIAN NEUTROPENIA REGISTRY

EHA Library, Piero Farruggia, 100505

PRELIMINARY DATA ON THE OUTCOME OF BONE MARROW TRANSPLANTATION IN CONGENITAL DISKERATOSIS. AN ANALYSIS FROM THE EUROPEAN GROUP FOR BONE MARROW TRANSPLANTATION (EBMT).

EHA Library, Francesca Fioredda, 100506

SOLUBLE CD163 AS A MARKER FOR MACROPHAGE ACTIVATION IN CHILDREN AND ADOLESCENTS WITH GAUCHER DISEASE: RELATION TO PULMONARY AND BONE INVOLVEMENT

EHA Library, Amira AM Adly, 100507

THE PROGNOSIS OF ACQUIRED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN ADULTS IS HEAVILY AFFECTED BY A COEXISTING VIRAL INFECTION: ANALYSIS OF A SINGLE INSTITUTION SERIES OF 35 PATIENTS

EHA Library, Chiara Cattaneo, 100508

A COMPREHENSIVE GENOME-WIDE COPY NUMBER ALTERATIONS (CNAS) ANALYSIS OF HOMOGENEOUSLY TREATED, NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS.

EHA Library, Carolina Terragna, 100509

RELATIONSHIP BETWEEN INHIBITION PROFILE OF Β1, Β2 AND Β5 PROTEASOME SUBUNITS AND CYTOTOXIC ACTIVITY OF PROTEASOME INHIBITORS IN MULTIPLE MYELOMA

EHA Library, Andrej Besse, 100510

S1P MODULATOR FTY720 TARGETS OSTEOCLASTOGENESIS IN CXCR4-BASED MULTIPLE MYELOMA SYSTEMIC XENOGRAFT MODEL

EHA Library, Katia Beider, 100511

PTC-209, A TRANSCRIPTIONAL SMALL MOLECULE INHIBITOR OF BMI-1, DEMONSTRATES POTENT ANTI-MYELOMA ACTIVITY IN VITRO

EHA Library, Arnold Bolomsky, 100512

POMALIDOMIDE ENHANCES THE ACTIVATION OF ANTI-MYELOMA SPECIFIC T CELLS IN HEALTHY DONORS AND MULTIPLE MYELOMA PATIENTS

EHA Library, Jingying Dai, 100513

LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES.

EHA Library, Federica Costa, 100514

P21-ACTIVATED KINASE 4 (PAK4) REGULATES MULTIPLE MYELOMA (MM) CELL GROWTH AND SURVIVAL BY MODULATION OF CRITICAL TRANSCRIPTIONAL PATHWAYS: THERAPEUTIC APPLICATION OF PAK4 ALLOSTERIC INHIBITORS

EHA Library, Maria Teresa Fulciniti, 100515

BONE MARROW-MEDIATED DRUG RESISTANCE IS PROMOTED BY JAGGED-INDUCED NOTCH PATHWAY IN MULTIPLE MYELOMA

EHA Library, Silvia Garavelli, 100516

FDG-PET/CT FOCAL LESIONS IN THE ABSENCE OF OSTEOLYSES AS A NEW MARKER OF PROGRESSION OF SMOLDERING MULTIPLE MYELOMA INTO SYMPTOMATIC DISEASE

EHA Library, Elena Zamagni, 100517

ANALYSIS OF OUTCOMES BY RESPONSE FOR PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN THE PHASE 3 PANORAMA 1 STUDY OF PANOBINOSTAT OR PLACEBO PLUS BORTEZOMIB AND DEXAMETHASONE

EHA Library, Philippe Moreau, 100518

WEEKLY CARFILZOMIB WITH DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 STUDY CHAMPION-1 (NCT01677858)

EHA Library, James Berenson, 100519

EARLY MORTALITY IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS: A POOLED ANALYSIS OF TWO LARGE RANDOMIZED PHASE III TRIALS

EHA Library, Alessandra Larocca, 100520

MAINTENANCE THERAPY WITH LENALIDOMIDE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST-HOC ANALYSIS OF THE EMN01 TRIAL.

EHA Library, Valeria Magarotto, 100521

OUTCOMES FOR OLDER PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE + LOW-DOSE DEXAMETHASONE IN THE STRATUS (MM-010) TRIAL, A SINGLE-ARM, PHASE 3B STUDY

EHA Library, Antonio Palumbo, 100522

THE STRATUS (MM-010) TRIAL: A SINGLE-ARM, PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE + LOW-DOSE DEXAMETHASONE IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA

EHA Library, Meletios Dimopoulos, 100523

IMPACT OF RENAL IMPAIRMENT ON OUTCOMES AFTER TREATMENT WITH LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: FIRST TRIAL RESULTS

EHA Library, Meletios Dimopoulos, 100524

AN OPEN-LABEL, MULTICENTER, PHASE 1B STUDY OF DARATUMUMAB IN COMBINATION WITH POMALIDOMIDE-DEXAMETHASONE AND WITH BACKBONE REGIMENS IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Maria Victoria Mateos, 100525

OUTCOMES OF PATIENTS WITH PRIMARY REFRACTORY MULTIPLE MYELOMA IN THE ERA OF NOVEL THERAPIES

EHA Library, Neil Majithia, 100526

ASSESSING THE BENEFIT OF CONTINUOUS TREATMENT IN THE FIRST TRIAL (MM-020): IMPACT OF RESPONSE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Nizar J Bahlis, 100527

LACK OF RESPONSE IMPROVEMENT BEYOND DAY +100 AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN ABSENCE OF MAINTENANCE THERAPY IN MULTIPLE MYELOMA

EHA Library, Carlos Fernandez Delarrea, 100528

RICOLINOSTAT (ACY-1215) THE FIRST SELECTIVE HDAC6 INHIBITOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED & REFRACTORY MULTIPLE MYELOMA: PHASE 1B & EARLY PHASE 2 RESULTS

EHA Library, Noopur Raje, 100529

PROGRESSION-FREE SURVIVAL 2 (PFS2) IS THE MOST SIGNIFICANT PROGNOSTIC FACTOR OF LONG-TERM SURVIVAL IN THE ERA OF NOVEL AGENTS: A SINGLE GREEK MYELOMA CENTER EXPERIENCE.

EHA Library, Eirini Katodritou, 100530

OBESITY AND RISK OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: A POPULATION-BASED STUDY

EHA Library, Marianna Thordardottir, 100531

POST AUTOLOGOUS STEM CELL TRANSPLANTATION MAINTENANCE IN MULTIPLE MYELOMA. SINGLE CENTER EXPERIENCE OF 18 YEARS: A MARKED SURVIVAL ADVANTAGE WITH INTERFERON.

EHA Library, Gergely Varga, 100532

WHOLE BODY DIFFUSION WEIGHTED MRI SCANNING IN PATIENTS WITH MYELOMA. INCIDENTAL FINDINGS - THE ROYAL MARSDEN EXPERIENCE.

EHA Library, Charlotte PAWLYN, 100533

PATTERNS OF TOTAL COST OF CARE BY AGE GROUP FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)

EHA Library, Steven Arikian, 100534

ENCOURAGING PRELIMINARY DATA IN ONGOING OPEN-LABEL PHASE 1/2 STUDY OF SAFETY AND EFFICACY OF MELFLUFEN AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED-REFRACTORY MULTIPLE MYELOMA

EHA Library, Valeria Magarotto, 100535

ANALYSIS OF PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT TREATED WITH POMALIDOMIDE + LOW-DOSE DEXAMETHASONE IN THE PHASE 3B STRATUS TRIAL (MM-010)

EHA Library, Katja Weisel, 100536

PROGNOSTIC VALUE AND USEFULNESS OF SERUM-FREE-LIGHT-CHAINS-RATIO (SFLCR) AND SERUM HEAVY-LIGHT-CHAINS-RATIO (SHLCR) IN SYMPTOMATIC MULTIPLE MYELOMA IN THE CONTEXT OF THREE GEM/PETHEMA CLINICAL TRIALS

EHA Library, Lucia Lopez-Anglada Fernandez, 100537

VENETOCLAX (ABT-199/GDC-0199) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA : PHASE 1B RESULTS

EHA Library, Philippe Moreau, 100538

RETROSPECTIVE REFINING OF DIAGNOSIS IN 286 MGUS AND SMM PATIENTS ACCORDING TO THE UPDATED IMWG CRITERIA. CLINICAL IMPLICATIONS

EHA Library, Eftychia Nikolaou, 100539

IS A DEEP RESPONSE THE KEY TO SUCCESSFUL TREATMENT OF MULTIPLE MYELOMA?

EHA Library, Johan Liwing, 100540

FAMILY HISTORY OF LYMPHOPROLIFERATIVE DISEASE ASSOCIATED WITH A SUPERIOR SURVIVAL IN MULTIPLE MYELOMA: A POPULATION-BASED STUDY

EHA Library, Kristrún Aradóttir, 100541